NDATOPICALPATCH
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZTLIDO (lidocaine) by PharmaIN is clinical pharmacology mechanism of action: lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 2018.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZTLIDO is a topical lidocaine patch delivering 5% lidocaine for localized pain relief via transdermal administration. Lidocaine works by stabilizing neuronal membranes and inhibiting ionic fluxes required for impulse initiation and conduction, producing local anesthetic effects within 3–5 minutes. The patch formulation enables non-systemic delivery to intact or compromised skin surfaces.
$0.051BPart D
Peak4.9 years to LOEProduct is at peak lifecycle stage with stable Part D spending of $51M annually (78,603 claims in 2023), indicating mature market penetration and a stable brand team structure.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of action: Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Onset of anesthesia: Lidocaine Ointment 5% effects local, topical anesthesia. The…
Worked on ZTLIDO at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.